ACADIA PHARMACEUTICALS INC (ACAD) Stock Price, Quote, News and Overview
NASDAQ:ACAD - Nasdaq - US0042251084 - Common Stock - Currency: USD
ACAD Quote, Performance and Key Statistics
24.04
+0.51 (+2.17%)
The current stock price of ACAD is 24.04 USD. In the past month the price increased by 15.13%. In the past year, price increased by 53.81%.
ACAD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.62 | 348.32B | ||
| AMGN | AMGEN INC | 14.54 | 162.36B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 142.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 121.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.52 | 61.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 54.71B | ||
| ARGX | ARGENX SE - ADR | 74.47 | 42.25B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.82 | 32.93B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.45B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.78B | ||
| INSM | INSMED INC | N/A | 21.10B | ||
| BIIB | BIOGEN INC | 8.26 | 19.37B |
Related stock screener links
About ACAD
Company Profile
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 653 full-time employees. The company went IPO on 2004-05-27. The company develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
Company Info
ACADIA PHARMACEUTICALS INC
12830 El Camino Real, Suite 400
San Diego CALIFORNIA 92130 US
CEO: Stephen R. Davis
Employees: 653
Phone: 18585582871
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What is the stock price of ACADIA PHARMACEUTICALS INC today?
The current stock price of ACAD is 24.04 USD. The price increased by 2.17% in the last trading session.
What is the ticker symbol for ACADIA PHARMACEUTICALS INC stock?
The exchange symbol of ACADIA PHARMACEUTICALS INC is ACAD and it is listed on the Nasdaq exchange.
On which exchange is ACAD stock listed?
ACAD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ACADIA PHARMACEUTICALS INC stock?
26 analysts have analysed ACAD and the average price target is 28.96 USD. This implies a price increase of 20.45% is expected in the next year compared to the current price of 24.04. Check the ACADIA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ACADIA PHARMACEUTICALS INC worth?
ACADIA PHARMACEUTICALS INC (ACAD) has a market capitalization of 4.02B USD. This makes ACAD a Mid Cap stock.
How many employees does ACADIA PHARMACEUTICALS INC have?
ACADIA PHARMACEUTICALS INC (ACAD) currently has 653 employees.
What are the support and resistance levels for ACADIA PHARMACEUTICALS INC (ACAD) stock?
ACADIA PHARMACEUTICALS INC (ACAD) has a support level at 20.95 and a resistance level at 24.05. Check the full technical report for a detailed analysis of ACAD support and resistance levels.
Is ACADIA PHARMACEUTICALS INC (ACAD) expected to grow?
The Revenue of ACADIA PHARMACEUTICALS INC (ACAD) is expected to grow by 9.25% in the next year. Check the estimates tab for more information on the ACAD EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ACADIA PHARMACEUTICALS INC (ACAD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ACAD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ACAD, evaluating the profitability, health, valuation and growth aspects
- ACADIA PHARMACEUTICALS INC (ACAD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ACADIA PHARMACEUTICALS INC (ACAD) Sales and EPS estimates to see what analysts future expectations are.
- ACADIA PHARMACEUTICALS INC (ACAD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ACADIA PHARMACEUTICALS INC (ACAD) Insider and Institutional Ownership to learn about the owners and their transactions.
- ACADIA PHARMACEUTICALS INC (ACAD) Stock Chart to make your own analysis
- ACADIA PHARMACEUTICALS INC (ACAD) Latest news and press-releases to stay up to date.
Does ACADIA PHARMACEUTICALS INC (ACAD) stock pay dividends?
ACAD does not pay a dividend.
When does ACADIA PHARMACEUTICALS INC (ACAD) report earnings?
ACADIA PHARMACEUTICALS INC (ACAD) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of ACADIA PHARMACEUTICALS INC (ACAD)?
The PE ratio for ACADIA PHARMACEUTICALS INC (ACAD) is 49.06. This is based on the reported non-GAAP earnings per share of 0.49 and the current share price of 24.04 USD. Check the full fundamental report for a full analysis of the valuation metrics for ACAD.
What is the Short Interest ratio of ACADIA PHARMACEUTICALS INC (ACAD) stock?
The outstanding short interest for ACADIA PHARMACEUTICALS INC (ACAD) is 6.92% of its float. Check the ownership tab for more information on the ACAD short interest.
ACAD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ACAD. When comparing the yearly performance of all stocks, ACAD is one of the better performing stocks in the market, outperforming 91.18% of all stocks.
ACAD Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ACAD. While ACAD has a great health rating, its profitability is only average at the moment.
ACAD Financial Highlights
Over the last trailing twelve months ACAD reported a non-GAAP Earnings per Share(EPS) of 0.49. The EPS increased by 5000% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 22.99% | ||
| ROA | 20.23% | ||
| ROE | 29.93% | ||
| Debt/Equity | 0 |
ACAD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to ACAD. The Buy consensus is the average rating of analysts ratings from 26 analysts.
For the next year, analysts expect an EPS growth of 11.46% and a revenue growth 9.25% for ACAD